Attached files
| file | filename |
|---|---|
| 8-K - 8-K - QUEST DIAGNOSTICS INC | dgx-20200723.htm |
QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
•Second quarter revenues of $1.83 billion, down 6.4% from 2019
•Second quarter reported diluted earnings per share from continuing operations ("EPS") of $1.36, down 9.7% from 2019; and adjusted diluted EPS of $1.42, down 17.9% from 2019
•Second quarter cash provided by operations of $355 million, up 10.4% from 2019
•Reinstates full year outlook for 2020. Full year 2020 reported diluted EPS expected to be between $5.66 and $7.66 and adjusted diluted EPS to be between $6.60 and $8.60
SECAUCUS, N.J., July 23, 2020 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2020, which are consistent with the preliminary results reported on July 13, 2020.
“In one of the most challenging periods in our history, Quest Diagnostics stepped up and rapidly expanded COVID-19 testing for the country and delivered stronger-than-expected performance in the second quarter,” said Steve Rusckowski, Chairman, CEO and President, Quest Diagnostics. “Our base testing volume declined versus 2019 because of the pandemic and was partially offset by COVID-19 testing. I am proud of Quest’s employees who have been on the frontlines of healthcare, answering the call in fighting the COVID-19 pandemic.”
Mr. Rusckowski concluded: "Looking forward to the rest of the year, we will continue to expand COVID-19 testing capacity while also continuing to serve our customers as they continue to recover from the pandemic. We have re-established our financial outlook for the remainder of the year with a broad range that reflects uncertainty caused by the pandemic."
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||
| 2020 | 2019 | Change | 2020 | 2019 | Change | |||||||||||||||||||||||||||||||||
| (dollars in millions, except per share data) | ||||||||||||||||||||||||||||||||||||||
Reported: | ||||||||||||||||||||||||||||||||||||||
Net revenues | $ | 1,827 | $ | 1,953 | (6.4) | % | $ | 3,649 | $ | 3,844 | (5.1) | % | ||||||||||||||||||||||||||
Diagnostic Information Services revenues | $ | 1,764 | $ | 1,872 | (5.7) | % | $ | 3,508 | $ | 3,684 | (4.8) | % | ||||||||||||||||||||||||||
Revenue per requisition | 15.3 | % | 6.4 | % | ||||||||||||||||||||||||||||||||||
Requisition volume | (17.7) | % | (10.2) | % | ||||||||||||||||||||||||||||||||||
Organic requisition volume | (18.2) | % | (10.5) | % | ||||||||||||||||||||||||||||||||||
Operating income (a) | $ | 283 | $ | 307 | (7.6) | % | $ | 458 | $ | 555 | (17.5) | % | ||||||||||||||||||||||||||
Operating income as a percentage of net revenues (a) | 15.5 | % | 15.7 | % | (0.2) | % | 12.5 | % | 14.4 | % | (1.9) | % | ||||||||||||||||||||||||||
| Income from continuing operations attributable to Quest Diagnostics (a) | $ | 185 | $ | 206 | (10.1) | % | $ | 284 | $ | 370 | (23.3) | % | ||||||||||||||||||||||||||
Diluted EPS (a) | $ | 1.36 | $ | 1.51 | (9.7) | % | $ | 2.09 | $ | 2.71 | (23.0) | % | ||||||||||||||||||||||||||
| Cash provided by operations | $ | 355 | $ | 321 | 10.4 | % | $ | 602 | $ | 596 | 0.9 | % | ||||||||||||||||||||||||||
| Capital expenditures | $ | 82 | $ | 85 | (4.0) | % | $ | 165 | $ | 132 | 24.7 | % | ||||||||||||||||||||||||||
| Adjusted: | ||||||||||||||||||||||||||||||||||||||
Operating income | $ | 294 | $ | 352 | (16.2) | % | $ | 519 | $ | 638 | (18.7) | % | ||||||||||||||||||||||||||
Operating income as a percentage of net revenues | 16.1 | % | 18.0 | % | (1.9) | % | 14.2 | % | 16.6 | % | (2.4) | % | ||||||||||||||||||||||||||
| Income from continuing operations attributable to Quest Diagnostics | $ | 193 | $ | 237 | (18.3) | % | $ | 321 | $ | 427 | (24.7) | % | ||||||||||||||||||||||||||
Diluted EPS | $ | 1.42 | $ | 1.73 | (17.9) | % | $ | 2.36 | $ | 3.13 | (24.3) | % | ||||||||||||||||||||||||||
(a)For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, income from continuing operations attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.
1
Outlook Reinstated for full year 2020
The company reinstated its financial outlook for full year 2020 after withdrawing it in April 2020. Current estimates for full year 2020 results are as follows:
| Low | High | ||||||||||
| Net revenues | $8.0 billion | $8.6 billion | |||||||||
| Net revenues increase | 3.5% | 11.3% | |||||||||
| Reported diluted EPS | $5.66 | $7.66 | |||||||||
| Adjusted diluted EPS | $6.60 | $8.60 | |||||||||
| Cash provided by operations | At least $1.25 billion | ||||||||||
| Capital expenditures | $375 million | $400 million | |||||||||
Outlook ranges for full year 2020 reflect a number of assumptions that are subject to change based on uncertainties related to the impact of the COVID-19 pandemic. The company intends to provide further detail regarding these assumptions on its quarterly conference call today.
Note on Non-GAAP Financial Measures
As used in this press release the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, certain financial impacts resulting from the COVID-19 pandemic, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, and other items.
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on the company's website at www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 800-839-1170 for domestic callers or 402-998-0559 for international callers. No passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on July 23, 2020 until midnight Eastern Time on August 6, 2020. Anyone listening to the call is encouraged to read the company's periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect
2
management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.
For further information: Denny Moynihan, Quest Diagnostics (Media): 973-520-2800, Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
3
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Six Months Ended June 30, 2020 and 2019
(in millions, except per share data)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
| Net revenues | $ | 1,827 | $ | 1,953 | $ | 3,649 | $ | 3,844 | |||||||||||||||
| Operating costs and expenses and other operating income: | |||||||||||||||||||||||
| Cost of services | 1,221 | 1,265 | 2,491 | 2,509 | |||||||||||||||||||
| Selling, general and administrative | 360 | 362 | 707 | 746 | |||||||||||||||||||
| Amortization of intangible assets | 25 | 25 | 50 | 49 | |||||||||||||||||||
| Other operating income, net | (62) | (6) | (57) | (15) | |||||||||||||||||||
| Total operating costs and expenses, net | 1,544 | 1,646 | 3,191 | 3,289 | |||||||||||||||||||
| Operating income | 283 | 307 | 458 | 555 | |||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||
| Interest expense, net | (41) | (45) | (82) | (89) | |||||||||||||||||||
| Other income (expense), net | 13 | 3 | (3) | 12 | |||||||||||||||||||
| Total non-operating expenses, net | (28) | (42) | (85) | (77) | |||||||||||||||||||
Income from continuing operations before income taxes and equity in earnings of equity method investees | 255 | 265 | 373 | 478 | |||||||||||||||||||
Income tax expense | (66) | (63) | (92) | (113) | |||||||||||||||||||
| Equity in earnings of equity method investees, net of taxes | 4 | 17 | 18 | 30 | |||||||||||||||||||
| Income from continuing operations | 193 | 219 | 299 | 395 | |||||||||||||||||||
| Income from discontinued operations, net of taxes | — | 20 | — | 20 | |||||||||||||||||||
| Net income | 193 | 239 | 299 | 415 | |||||||||||||||||||
| Less: Net income attributable to noncontrolling interests | 8 | 13 | 15 | 25 | |||||||||||||||||||
| Net income attributable to Quest Diagnostics | $ | 185 | $ | 226 | $ | 284 | $ | 390 | |||||||||||||||
| Amounts attributable to Quest Diagnostics' common stockholders: | |||||||||||||||||||||||
| Income from continuing operations | $ | 185 | $ | 206 | $ | 284 | $ | 370 | |||||||||||||||
| Income from discontinued operations, net of taxes | — | 20 | — | 20 | |||||||||||||||||||
| Net income | $ | 185 | $ | 226 | $ | 284 | $ | 390 | |||||||||||||||
Earnings per share attributable to Quest Diagnostics’ common stockholders - basic: | |||||||||||||||||||||||
| Income from continuing operations | $ | 1.38 | $ | 1.52 | $ | 2.12 | $ | 2.74 | |||||||||||||||
| Income from discontinued operations | — | 0.15 | — | 0.15 | |||||||||||||||||||
| Net income | $ | 1.38 | $ | 1.67 | $ | 2.12 | $ | 2.89 | |||||||||||||||
Earnings per share attributable to Quest Diagnostics' common stockholders - diluted: | |||||||||||||||||||||||
| Income from continuing operations | $ | 1.36 | $ | 1.51 | $ | 2.09 | $ | 2.71 | |||||||||||||||
| Income from discontinued operations | — | 0.15 | — | 0.15 | |||||||||||||||||||
| Net income | $ | 1.36 | $ | 1.66 | $ | 2.09 | $ | 2.86 | |||||||||||||||
| Weighted average common shares outstanding: | |||||||||||||||||||||||
| Basic | 134 | 135 | 134 | 134 | |||||||||||||||||||
| Diluted | 136 | 136 | 135 | 136 | |||||||||||||||||||
4
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
June 30, 2020 and December 31, 2019
(in millions, except per share data)
(unaudited)
| June 30, 2020 | December 31, 2019 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 988 | $ | 1,192 | |||||||
| Accounts receivable, net | 1,126 | 1,063 | |||||||||
| Inventories | 154 | 123 | |||||||||
| Prepaid expenses and other current assets | 112 | 112 | |||||||||
| Total current assets | 2,380 | 2,490 | |||||||||
| Property, plant and equipment, net | 1,505 | 1,453 | |||||||||
| Operating lease right-of-use assets | 522 | 518 | |||||||||
| Goodwill | 6,789 | 6,619 | |||||||||
| Intangible assets, net | 1,141 | 1,121 | |||||||||
| Investments in equity method investees | 495 | 482 | |||||||||
| Other assets | 158 | 160 | |||||||||
| Total assets | $ | 12,990 | $ | 12,843 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued expenses | $ | 1,142 | $ | 1,041 | |||||||
| Current portion of long-term debt | 555 | 804 | |||||||||
| Current portion of long-term operating lease liabilities | 146 | 145 | |||||||||
| Total current liabilities | 1,843 | 1,990 | |||||||||
| Long-term debt | 4,020 | 3,966 | |||||||||
| Long-term operating lease liabilities | 416 | 413 | |||||||||
| Other liabilities | 753 | 711 | |||||||||
| Redeemable noncontrolling interest | 77 | 76 | |||||||||
| Stockholders’ equity: | |||||||||||
| Quest Diagnostics stockholders’ equity: | |||||||||||
| Common stock, par value $0.01 per share; 600 shares authorized as of both June 30, 2020 and December 31, 2019; 217 shares issued as of both June 30, 2020 and December 31, 2019 | 2 | 2 | |||||||||
| Additional paid-in capital | 2,764 | 2,722 | |||||||||
| Retained earnings | 8,307 | 8,174 | |||||||||
| Accumulated other comprehensive loss | (55) | (39) | |||||||||
| Treasury stock, at cost; 83 and 84 shares as of June 30, 2020 and December 31, 2019, respectively | (5,187) | (5,218) | |||||||||
| Total Quest Diagnostics stockholders’ equity | 5,831 | 5,641 | |||||||||
| Noncontrolling interests | 50 | 46 | |||||||||
| Total stockholders’ equity | 5,881 | 5,687 | |||||||||
| Total liabilities and stockholders’ equity | $ | 12,990 | $ | 12,843 | |||||||
5
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2020 and 2019
(in millions)
(unaudited)
| Six Months Ended June 30, | |||||||||||
| 2020 | 2019 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net income | $ | 299 | $ | 415 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 174 | 165 | |||||||||
| Provision for credit losses | 13 | 5 | |||||||||
| Deferred income tax provision | 23 | 13 | |||||||||
| Stock-based compensation expense | 31 | 32 | |||||||||
| Other, net | 3 | (33) | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | (75) | (81) | |||||||||
| Accounts payable and accrued expenses | 42 | 27 | |||||||||
| Income taxes payable | 51 | 15 | |||||||||
| Termination of interest rate swap agreements | 40 | — | |||||||||
| Other assets and liabilities, net | 1 | 38 | |||||||||
| Net cash provided by operating activities | 602 | 596 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Business acquisitions, net of cash acquired | (228) | (56) | |||||||||
| Capital expenditures | (165) | (132) | |||||||||
| Increase in investments and other assets | (18) | (14) | |||||||||
| Net cash used in investing activities | (411) | (202) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Proceeds from borrowings | 749 | 1,484 | |||||||||
| Repayments of debt | (1,001) | (1,448) | |||||||||
| Purchases of treasury stock | (75) | (103) | |||||||||
| Exercise of stock options | 117 | 66 | |||||||||
| Employee payroll tax withholdings on stock issued under stock-based compensation plans | (13) | (16) | |||||||||
| Dividends paid | (146) | (143) | |||||||||
| Distributions to noncontrolling interest partners | (10) | (27) | |||||||||
| Other financing activities, net | (16) | (69) | |||||||||
| Net cash used in financing activities | (395) | (256) | |||||||||
| Net change in cash and cash equivalents and restricted cash | (204) | 138 | |||||||||
| Cash and cash equivalents and restricted cash, beginning of period | 1,192 | 135 | |||||||||
| Cash and cash equivalents and restricted cash, end of period | $ | 988 | $ | 273 | |||||||
| Cash paid during the period for: | |||||||||||
| Interest | $ | 103 | $ | 91 | |||||||
| Income taxes | $ | 20 | $ | 83 | |||||||
6
Notes to Financial Tables
1)The computation of basic and diluted earnings per common share is as follows:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
| (in millions, except per share data) | |||||||||||||||||||||||
| Amounts attributable to Quest Diagnostics' common stockholders: | |||||||||||||||||||||||
| Income from continuing operations | $ | 185 | $ | 206 | $ | 284 | $ | 370 | |||||||||||||||
| Income from discontinued operations, net of taxes | — | 20 | — | 20 | |||||||||||||||||||
| Net income attributable to Quest Diagnostics' common stockholders | $ | 185 | $ | 226 | $ | 284 | $ | 390 | |||||||||||||||
| Income from continuing operations | $ | 185 | $ | 206 | $ | 284 | $ | 370 | |||||||||||||||
| Less: earnings allocated to participating securities | 1 | — | 1 | 1 | |||||||||||||||||||
Earnings available to Quest Diagnostics' common stockholders - basic and diluted | $ | 184 | $ | 206 | $ | 283 | $ | 369 | |||||||||||||||
| Weighted average common shares outstanding - basic | 134 | 135 | 134 | 134 | |||||||||||||||||||
| Effect of dilutive securities: | |||||||||||||||||||||||
| Stock options and performance share units | 2 | 1 | 1 | 2 | |||||||||||||||||||
| Weighted average common shares outstanding - diluted | 136 | 136 | 135 | 136 | |||||||||||||||||||
Earnings per share attributable to Quest Diagnostics' common stockholders - basic: | |||||||||||||||||||||||
| Income from continuing operations | $ | 1.38 | $ | 1.52 | $ | 2.12 | $ | 2.74 | |||||||||||||||
| Income from discontinued operations | — | 0.15 | — | 0.15 | |||||||||||||||||||
| Net income | $ | 1.38 | $ | 1.67 | $ | 2.12 | $ | 2.89 | |||||||||||||||
Earnings per share attributable to Quest Diagnostics' common stockholders - diluted: | |||||||||||||||||||||||
| Income from continuing operations | $ | 1.36 | $ | 1.51 | $ | 2.09 | $ | 2.71 | |||||||||||||||
| Income from discontinued operations | — | 0.15 | — | 0.15 | |||||||||||||||||||
| Net income | $ | 1.36 | $ | 1.66 | $ | 2.09 | $ | 2.86 | |||||||||||||||
7
2)The following tables reconcile reported GAAP results to non-GAAP adjusted results:
| Three Months Ended June 30, 2020 | |||||||||||||||||||||||||||||||||||
| (dollars in millions, except per share data) | |||||||||||||||||||||||||||||||||||
| Operating income | Operating income as a percentage of net revenues | Income tax expense (d) | Equity in earnings of equity method investees, net of taxes | Income from continuing operations attributable to Quest Diagnostics | Diluted EPS | ||||||||||||||||||||||||||||||
| As reported | $ | 283 | 15.5 | % | $ | (66) | $ | 4 | $ | 185 | $ | 1.36 | |||||||||||||||||||||||
| Restructuring and integration charges (a) | 9 | 0.6 | (1) | — | 8 | 0.06 | |||||||||||||||||||||||||||||
| COVID-19 impact (b) | (23) | (1.3) | 10 | (3) | (17) | (0.13) | |||||||||||||||||||||||||||||
| Amortization expense | 25 | 1.3 | (7) | 3 | 21 | 0.16 | |||||||||||||||||||||||||||||
| ETB | — | — | (4) | — | (4) | (0.03) | |||||||||||||||||||||||||||||
| As adjusted | $ | 294 | 16.1 | % | $ | (68) | $ | 4 | $ | 193 | $ | 1.42 | |||||||||||||||||||||||
| Six Months Ended June 30, 2020 | |||||||||||||||||||||||||||||||||||
| (dollars in millions, except per share data) | |||||||||||||||||||||||||||||||||||
| Operating income | Operating income as a percentage of net revenues | Income tax expense (d) | Equity in earnings of equity method investees, net of taxes | Income from continuing operations attributable to Quest Diagnostics | Diluted EPS | ||||||||||||||||||||||||||||||
| As reported | $ | 458 | 12.5 | % | $ | (92) | $ | 18 | $ | 284 | $ | 2.09 | |||||||||||||||||||||||
| Restructuring and integration charges (a) | 25 | 0.7 | (5) | — | 20 | 0.15 | |||||||||||||||||||||||||||||
| COVID-19 impact (b) | (14) | (0.4) | 7 | (3) | (13) | (0.10) | |||||||||||||||||||||||||||||
| Amortization expense | 50 | 1.4 | (14) | 6 | 42 | 0.31 | |||||||||||||||||||||||||||||
| ETB | — | — | (12) | — | (12) | (0.09) | |||||||||||||||||||||||||||||
| As adjusted | $ | 519 | 14.2 | % | $ | (116) | $ | 21 | $ | 321 | $ | 2.36 | |||||||||||||||||||||||
| Three Months Ended June 30, 2019 | |||||||||||||||||||||||||||||||||||
| (dollars in millions, except per share data) | |||||||||||||||||||||||||||||||||||
| Operating income | Operating income as a percentage of net revenues | Income tax expense (d) | Equity in earnings of equity method investees, net of taxes | Income from continuing operations attributable to Quest Diagnostics | Diluted EPS | ||||||||||||||||||||||||||||||
| As reported | $ | 307 | 15.7 | % | $ | (63) | $ | 17 | $ | 206 | $ | 1.51 | |||||||||||||||||||||||
| Restructuring and integration charges (a) | 26 | 1.3 | (7) | — | 19 | 0.14 | |||||||||||||||||||||||||||||
| Other (c) | (6) | (0.3) | — | — | (6) | (0.04) | |||||||||||||||||||||||||||||
| Amortization expense | 25 | 1.3 | (7) | 5 | 23 | 0.16 | |||||||||||||||||||||||||||||
| ETB | — | — | (5) | — | (5) | (0.04) | |||||||||||||||||||||||||||||
| As adjusted | $ | 352 | 18.0 | % | $ | (82) | $ | 22 | $ | 237 | $ | 1.73 | |||||||||||||||||||||||
8
| Six Months Ended June 30, 2019 | |||||||||||||||||||||||||||||||||||
| (dollars in millions, except per share data) | |||||||||||||||||||||||||||||||||||
| Operating income | Operating income as a percentage of net revenues | Income tax expense (d) | Equity in earnings of equity method investees, net of taxes | Income from continuing operations attributable to Quest Diagnostics | Diluted EPS | ||||||||||||||||||||||||||||||
| As reported | $ | 555 | 14.4 | % | $ | (113) | $ | 30 | $ | 370 | $ | 2.71 | |||||||||||||||||||||||
| Restructuring and integration charges (a) | 48 | 1.3 | (13) | — | 35 | 0.26 | |||||||||||||||||||||||||||||
| Other (c) | (14) | (0.4) | (1) | — | (15) | (0.10) | |||||||||||||||||||||||||||||
| Amortization expense | 49 | 1.3 | (14) | 10 | 45 | 0.32 | |||||||||||||||||||||||||||||
| ETB | — | — | (8) | — | (8) | (0.06) | |||||||||||||||||||||||||||||
| As adjusted | $ | 638 | 16.6 | % | $ | (149) | $ | 40 | $ | 427 | $ | 3.13 | |||||||||||||||||||||||
(a)For both the three and six months ended June 30, 2020 and 2019, represents costs primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on the company's consolidated statements of operations:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
| (dollars in millions) | |||||||||||||||||||||||
| Cost of services | $ | 3 | $ | 11 | $ | 10 | $ | 22 | |||||||||||||||
| Selling, general and administrative | 6 | 15 | 15 | 26 | |||||||||||||||||||
| Operating income | $ | 9 | $ | 26 | $ | 25 | $ | 48 | |||||||||||||||
(b)For both the three and six months ended June 30, 2020, represents the impact of certain items resulting from the COVID-19 pandemic including $65 million of income recognized attributable to the receipt of the initial tranche of funds from the government that were appropriated to healthcare providers under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), partially offset by expense associated with a one-time payment to eligible employees to help offset expenses they incurred as a result of COVID-19, certain asset impairment charges, and incremental costs incurred primarily to protect the health and safety of the company's employees and customers.
The following table summarizes the pre-tax impact of these COVID-19 items on the company's consolidated statements of operations:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
| (dollars in millions) | |||||||||||||||||||||||
| Cost of services | $ | 34 | $ | — | $ | 35 | $ | — | |||||||||||||||
| Selling, general and administrative | 5 | — | 8 | — | |||||||||||||||||||
| Other operating income, net | (62) | — | (57) | — | |||||||||||||||||||
| Operating income | $ | (23) | $ | — | $ | (14) | $ | — | |||||||||||||||
| Net income attributable to noncontrolling interest | $ | 1 | $ | — | $ | 3 | $ | — | |||||||||||||||
(c)For the three months ended June 30, 2019, the pre-tax impact primarily represents a gain associated with the decrease in the fair value of the contingent consideration accrual associated with a previous acquisition. For the six months ended June 30, 2019, the pre-tax impact primarily represents a gain associated with an insurance claim for hurricane related losses, and a gain associated with the decrease in the fair value of the contingent consideration accrual associated with a previous acquisition, partially offset by non-cash asset impairment charges. The following table summarizes the pre-tax impact of these other items on the company's consolidated statements of operations:
9
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
| (dollars in millions) | |||||||||||||||||||||||
| Selling, general and administrative | $ | — | $ | — | $ | — | $ | 1 | |||||||||||||||
| Other operating income, net | — | (6) | — | (15) | |||||||||||||||||||
| Operating income | $ | — | $ | (6) | $ | — | $ | (14) | |||||||||||||||
(d)For restructuring and integration charges, COVID-19 impacts, other items and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2020 and 2019. For the gain associated with an insurance claim for hurricane related losses in 2019, there was no net income tax expense as the company was able to utilize net operating loss carryforwards for which a valuation allowance had previously been established. For the gain in 2019 associated with the decrease in the fair value of the contingent consideration accrual associated with a previous acquisition, there was no net income tax expense as the gain is non-taxable.
3)Discontinued operations, net of taxes, for the three and six months ended June 30, 2019 includes discrete tax benefits of $20 million associated with the favorable resolution of certain tax contingencies related to Nichols Institute Diagnostics, a test kit manufacturing subsidiary whose operations were discontinued in 2006.
4)For the three months ended June 30, 2020, the company did not repurchase any shares of its common stock. For the six months ended June 30, 2020, the company repurchased 0.7 million shares of its common stock for $75 million. As of June 30, 2020, $1.2 billion remained available under the company’s share repurchase authorizations; however the company has temporarily suspended additional share repurchases under the existing authorization through the end of 2020.
5)For the six months ended June 30, 2020, net cash provided by operating activities includes $65 million that the company received from the initial tranche of funds that were appropriated to healthcare providers under the CARES Act.
6)The outlook for adjusted diluted EPS represents management’s estimates for the full year 2020 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2020. Both reported and adjusted diluted EPS exclude any proceeds that we may receive from the secondary tranche of funds distributed to healthcare providers under the CARES Act. Additionally, the amount of ETB is dependent upon employee stock option exercises and the company's stock price, which are difficult to predict. The following table reconciles our 2020 outlook for adjusted diluted EPS to the corresponding amounts determined under GAAP:
| Low | High | ||||||||||
| Diluted EPS | $ | 5.66 | $ | 7.66 | |||||||
| Restructuring and integration charges (a) | 0.50 | 0.50 | |||||||||
| COVID-19 impact | (0.10) | (0.10) | |||||||||
| Amortization expense (b) | 0.65 | 0.65 | |||||||||
| ETB | (0.11) | (0.11) | |||||||||
| Adjusted diluted EPS | $ | 6.60 | $ | 8.60 | |||||||
(a)Represents estimated full year pre-tax charges of $90 million primarily associated with systems conversions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were calculated using a combined statutory income tax rate of 25.5%.
(b)Represents the estimated impact of amortization expense for 2020 on the calculation of adjusted diluted EPS. Amortization expense used in the calculation is as follows (dollars in millions):
10
| Amortization of intangible assets | $ | 107 | |||
| Amortization expense included in equity in earnings of equity method investees, net of taxes | 11 | ||||
| Total pre-tax amortization expense | $ | 118 | |||
| Total amortization expense, net of an estimated tax benefit using a combined statutory income tax rate of 25.5% | $ | 88 | |||
11